<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Boulate D</submitter><funding>CRC3F</funding><funding>Institut National Du Cancer</funding><funding>Astra Zeneca</funding><pagination>e067191</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9806070</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(12)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Eligibility criteria definition for a lung cancer screening (LCS) is an unmet need. We hypothesised that patients with a history of atheromatous cardiovascular disease (ACVD) associated with tobacco consumption are at risk of lung cancer (LC). The main objective is to assess LC prevalence among patients with ACVD and history of tobacco consumption by using low-dose chest CT scan. Secondary objectives include the evaluation LCS in this population and the constitution of a biological biobank to stratify risk of LC.&lt;h4>Methods and analysis&lt;/h4>We are performing a monocentric 'single-centre' prospective study among patients followed up in adult cardiovascular programmes of vascular surgery, cardiology and cardiac surgery recruited from 18 November 2019 to 18 May 2021. The </pubmed_abstract><journal>BMJ open</journal><pubmed_title>Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol.</pubmed_title><pmcid>PMC9806070</pmcid><funding_grant_id>N/A</funding_grant_id><funding_grant_id>TABAC 18-012</funding_grant_id><pubmed_authors>Caramella C</pubmed_authors><pubmed_authors>Mercier O</pubmed_authors><pubmed_authors>Chatellier G</pubmed_authors><pubmed_authors>Boulate D</pubmed_authors><pubmed_authors>Garelik D</pubmed_authors><pubmed_authors>Pradere P</pubmed_authors><pubmed_authors>Zins M</pubmed_authors><pubmed_authors>Beaussier H</pubmed_authors><pubmed_authors>Fidelle M</pubmed_authors><pubmed_authors>Planche O</pubmed_authors><pubmed_authors>Lamrani L</pubmed_authors><pubmed_authors>Zitvogel L</pubmed_authors><pubmed_authors>Besse B</pubmed_authors><pubmed_authors>Hache O</pubmed_authors><pubmed_authors>Issard J</pubmed_authors><pubmed_authors>Fadel E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol.</name><description>&lt;h4>Introduction&lt;/h4>Eligibility criteria definition for a lung cancer screening (LCS) is an unmet need. We hypothesised that patients with a history of atheromatous cardiovascular disease (ACVD) associated with tobacco consumption are at risk of lung cancer (LC). The main objective is to assess LC prevalence among patients with ACVD and history of tobacco consumption by using low-dose chest CT scan. Secondary objectives include the evaluation LCS in this population and the constitution of a biological biobank to stratify risk of LC.&lt;h4>Methods and analysis&lt;/h4>We are performing a monocentric 'single-centre' prospective study among patients followed up in adult cardiovascular programmes of vascular surgery, cardiology and cardiac surgery recruited from 18 November 2019 to 18 May 2021. The </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-05-27T11:00:28.983Z</modification><creation>2024-11-09T22:38:07.452Z</creation></dates><accession>S-EPMC9806070</accession><cross_references><pubmed>36572501</pubmed><doi>10.1136/bmjopen-2022-067191</doi></cross_references></HashMap>